921P HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer.

Autor:	Nabell, L.1 (AUTHOR), Ho, A.L.2 (AUTHOR), Posner, M.R.3 (AUTHOR), Neupane, P.4 (AUTHOR), Naqash, A-R.5 (AUTHOR), Wong, S.6 (AUTHOR), Niu, J.J.7 (AUTHOR), Pearson, A.T.8 (AUTHOR), Laux, D.9 (AUTHOR), Adkins, D.R.10 (AUTHOR), Pimentel, A.11 (AUTHOR), Rosenberg, A.J.8 (AUTHOR), Richardson, D.L.5 (AUTHOR), Wong, W.2 (AUTHOR), Kaufmann, T.A.12 (AUTHOR), Katchar, K.13 (AUTHOR), Qing, X.14 (AUTHOR), Iacobucci, C.14 (AUTHOR), Schlienger, K.14 (AUTHOR), Pfister, D.2 (AUTHOR)
Zdroj:	Annals of Oncology. 2023 Supplement 2, Vol. 34, pS581-S582. 2p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu